OncoSec Medical Inc (ONCSQ)

[guti]

If they had nothing to say, they would not be setting themselves up for such important forums.
They have already registered for the 22nd International Molecular Medicine Tri-Conference which is the industry's preeminent event on molecular medicine, focusing on drug discovery, genomics, diagnostics and information technology. On Tuesday Feb.17, on a forum titled Translational to Clinical R&D “Strategies and Technologies to Reduce Attrition and Improve Clinical Outcomes” OncoSec will present in the morning alongside a group of companies that stand with great value, GlaxoSmithKline, Genentech and Merck. Robert Pierce will speak of data titled Translational Approaches for the Development of Intratumoral Immunotherapies. In it he will discuss Intratumoral therapies are capable of reversing local immunosuppressive mechanisms and driving systemic anti-tumor immune responses. Given the safety and potential systemic efficacy of this approach, Intratumoral therapies will likely play a growing role in future combination immunotherapy regimens. The pros and cons of current syngeneic mouse models will be addressed with particular emphasis on unique aspects of intratumoral therapies. A month before that OncoSec will be at 2:30 pm, Tuesday January 13, Biotech Showcase 2015, where Punit will be attracting new investors and building a stronger case for partnership. In the mean time they will start the month of November broaden the horizons in Europe with the BIO-Europe 2014 presenting at 11:30, Tuesday, November 4. This is just getting started, since they are planning for a long future, and at this point in time, it is easy to see where it is heading. OncoSec just received the equivalent of acceptance to Harvard with a scholarship, as they plan to improve on their product with a SBIR program through NIH. And they will graduate.